Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8870506 | 0.91 | EGFR (0.76) | EGFRABCG2ERBB2MAPK1HTT | |
| SCHEMBL18349251 | 0.87 | EGFR (0.77) | EGFRABCG2ERBB2ALKHTT | |
| SCHEMBL1192454 | 0.86 | EGFR (1.00) | EGFRABCG2MAPK1ALKHTT | |
| SCHEMBL8871973 | 0.86 | EGFR (0.83) | EGFRABCG2ERBB2ALKHTT | |
| SCHEMBL4587413 | 0.86 | EGFR (0.83) | EGFRABCG2ALKHTTALDH1A1 | |
| SCHEMBL3244621 | 0.86 | EGFR (1.00) | EGFRABCG2ERBB2ALK | |
| SCHEMBL30552991 | 0.86 | EGFR (1.00) | EGFRABCG2ERBB2ALK | |
| SCHEMBL6665852 | 0.84 | ALK (0.70) | EGFRABCG2ERBB2MAPK1ALK | |
| SCHEMBL8871863 | 0.83 | EGFR (0.82) | EGFRERBB2MAPK1NCOA1NCOA3 | |
| SCHEMBL8871526 | 0.83 | EGFR (0.71) | EGFRABCG2ALKHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0520722-B1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LTD (GB) | 1996-12-27 | — | — | EP | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
| EP-0520722-A1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | disclosed |